Highlights and Quick Summary
- Research and Development Expense of Revenue for the quarter ending September 30, 2022 was 69.55% (a -26.48% decrease compared to previous quarter)
- Year-over-year quarterly Research and Development Expense of Revenue decreased by -48.37%
- Annual Research and Development Expense of Revenue for 2021 was 132.85% (a -80.76% decrease from previous year)
- Annual Research and Development Expense of Revenue for 2020 was 690.34% (a 214.88% increase from previous year)
- Annual Research and Development Expense of Revenue for 2019 was 219.24% (a -46.66% decrease from previous year)
- Twelve month Research and Development Expense of Revenue ending September 30, 2022 was 102.17% (a -13.63% decrease compared to previous quarter)
- Twelve month trailing Research and Development Expense of Revenue decreased by -23.09% year-over-year
Trailing Research and Development Expense of Revenue for the last four month:
| 30 Sep '22 | 30 Jun '22 | 31 Mar '22 | 31 Dec '21 |
|---|---|---|---|
| 102.17% | 118.29% | 123.24% | 132.85% |
Visit stockrow.com/BCRX
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Research and Development Expense of Revenue of BioCryst Pharmaceuticals, Inc.
Most recent Research and Development Expense of Revenueof BCRX including historical data for past 10 years.Interactive Chart of Research and Development Expense of Revenue of BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. Research and Development Expense of Revenue for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | – | 69.55% | 94.6% | 130.92% | – |
| 2021 | 134.72% | 121.9% | 105.83% | 222.65% | 132.85% |
| 2020 | 880.33% | 495.66% | 957.78% | 619.26% | 690.34% |
| 2019 | 67.4% | 1415.21% | 1911.67% | 467.01% | 219.24% |
| 2018 | 858.59% | 1513.48% | 168.16% | 463.81% | 411.02% |
| 2017 | 435.06% | 199.87% | 508.52% | 177.7% | 265.87% |
| 2016 | 135.34% | 181.7% | 295.93% | 426.95% | 231.5% |
| 2015 | 413.89% | 182.64% | 63.94% | 250.81% | 150.77% |
| 2014 | 339.88% | 402.59% | 754.91% | 265.56% | 380.63% |
| 2013 | 146.36% | 323.78% | 1404.02% | 203.01% | 242.01% |
| 2012 | 214.24% | 209.55% | 303.49% | 127.04% | 186.97% |
Business Profile of BioCryst Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology